Lowering the High Cost of Hepatitis C Drugs

Chapman, Audrey R.; Buckley, Thomas

doi:10.4172/2376-0419.1000187

Cited by 3 publications

(2 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The production of lifesaving drugs by overbearing pharmaceutical companies is not unique to the insulin market. Hepatitis C antiviral therapies, for example, are classified as an "essential medication" by the World Health Organization (Chapman and Buckley 2017). In the U.S., approximately 1.2 to 4.7 million people-predominantly low-income-are diagnosed with Hepatitis C, making it one of the most common blood-borne infections.…”

Section: Appendixmentioning

confidence: 99%

“…In the U.S., approximately 1.2 to 4.7 million people-predominantly low-income-are diagnosed with Hepatitis C, making it one of the most common blood-borne infections. However, the price of a 12-week treatment regimen ranges from $54,000 to $94,500 per person before insurance or rebates (National Academies of Sciences, Engineering, and Medicine et al 2016, 111;Chapman and Buckley 2017). This high price of life-saving drugs coupled with a large demand for treatment has pushed both public and private insurers to impose restrictions excluding people from obtaining the treatment they require.…”

Section: Appendixmentioning

confidence: 99%

See 1 more Smart Citation

Federal Policy for Lowering Prescription Drug Prices

Hurley

Sheftel

Canales

2020

JSPG

View full text Add to dashboard Cite

Both Republicans and Democrats are determined to lower the escalating cost of prescription drug prices, which is projected to reach $605 billion/yr by 2026 (Committee on Ways and Means 2019). In this memorandum, we explore the possible outcomes of, 1) linking U.S. drug prices to the international median incentivized by re-importation of the U.S.-made drugs from other countries, 2) allowing the Secretary of Health and Human Services (HHS) to negotiate Medicare part D drugs incentivized through patent exemption and, 3) funding drug discovery through prizes instead of market-exclusive patents. We recommend that the next presidential candidate approve Option 2 and advocate for HHS Secretary negotiation powers with patent exemptions for non-compliant companies.

show abstract

Section: Appendixmentioning

confidence: 99%

Section: Appendixmentioning

confidence: 99%